RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
RANTES (regulated upon activation, normal T-cell expressed and secreted), a CC chemokine, appears to play a role in the pathogenesis of relapsing-remitting multiple sclerosis (RR-MS), enhancing the inflammatory response within the nervous system. We have demonstrated that RANTES production is increased in RR-MS compared to controls. Interferon-beta-1b (IFN-beta-1b) treatment reduces RANTES production in sera and peripheral blood adherent mononuclear cell (PBAM) supernatants both in relapse and remission. IFN-beta-1b also reduces RANTES expression in PBAM. Our results suggest that RANTES modulation might represent one of the mechanisms of action of IFN-beta-1b in RR-MS.
Iarlori
C
C
Department of Oncology and Neuroscience, Neuroimmunology Unit, University 'Gabriele d'Annunzio', Via dei Vestini, 66013, Chieti, Italy.
Reale
M
M
Lugaresi
A
A
De Luca
G
G
Bonanni
L
L
Di Iorio
A
A
Feliciani
C
C
Conti
P
P
Gambi
D
D
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D018946:Chemokine CCL5 / Q000096:biosynthesis / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D010835:Phytohemagglutinins / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000276:Adjuvants, Immunologic; D018946:Chemokine CCL5; D010835:Phytohemagglutinins; D012333:RNA, Messenger; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a